Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: This study aimed to compare the potential diagnostic efficacy of gallium68-fibroblast-activation protein inhibitor ([Ga]Ga-FAPI-04) and fluorine18-fluorodeoxyglucose ([F]-FDG) positron emission tomography-computed tomography (PET/CT) for primary tumors, lymph nodes, and distant metastatic lesions of gastric cancer (GC), and to explore the effects of [Ga]Ga-FAPI-04 and [F]-FDG on tumor staging and restaging in GC.
Methods: This single-center retrospective study (NCT2100044131) was conducted at the Affiliated Hospital of the Southwest Medical University between June 2020 and December 2021. Images of patients with GC who were pathologically confirmed and underwent contemporaneous [F]-FDG and [Ga]Ga-FAPI-04 PET/CT within 1 week were analyzed. The diagnostic efficacy of [Ga]Ga-FAPI-04 PET/CT and [F]-FDG PET/CT for TNM staging of GC was compared using McNemar test. The maximum standard uptake value (SUVmax) of each lesion in the two imaging types was compared using the Mann-Whitney U test.
Results: In total, 25 patients with GC (mean age, 56 ± 12 years) were evaluated. [Ga]Ga-FAPI-04 PET/CT exhibited higher sensitivity compared to [F]-FDG PET/CT for detecting primary tumors (18/19 [94.74%] vs. 13/19 [68.42%], χ2 = 6.866, P < 0.01), lymph node metastasis (75/77 [97.40%] vs. 32/77 [41.56%], χ2 = 2.888, P =0.089), and distant metastases (275/283 [97.17%] vs. 122/283 [43.11%], χ2 = 11.858, P < 0.01). [Ga]Ga-FAPI-04 accumulation was significantly higher than that of [F]FDG in tumors (median SUVmax, 10.28 vs 3.20; U=59.00, P < 0.01), lymph node metastasis metastases (median SUVmax, 9.20 vs 3.15; U=53.50, P < 0.01), and distant metastases (median SUVmax, 8.00 vs 4.20; U=200.00, P < 0.01). Compared to [F]-FDG PET/CT, [Ga]Ga-FAPI-04 PET/CT resulted in new oncological findings in 14/25 patients and corrected tumor staging or restaging in 7/25 patients.
Conclusion: Our preliminary results regarding the impact of [Ga]Ga-FAPI-04 PET/CT on tumor staging highlight the potential of this approach for increasing the accuracy of GC diagnosis, which may facilitate treatment decision-making.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283765 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.925100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Same-day dual-tracer PET/CT imaging with [ Ga]Ga-FAPI-04 following [F]FDG finds answers in patients presenting with negative or equivocal [F]FDG.
Ann Nucl Med
July 2025
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Objective: Gallium-68-labelled fibroblast activation protein inhibitor ([ Ga]Ga-FAPI) is a tumour-stromal imaging agent showing complementary value alongside fluorine-18 fluorodeoxyglucose ([F]FDG) in cancer imaging. This study investigated the feasibility of a same-day dual-tracer positron emission tomography/computed tomography (PET/CT) protocol with [ Ga]Ga-FAPI-04 following [F]FDG in patients presenting with negative or equivocal [F]FDG.
Methods: Patients with negative or equivocal [F]FDG findings underwent dual-tracer PET/CT (named FDG-mixed FAPI PET/CT, abbreviated to mFAPI PET/CT) on the same day, with [ Ga]Ga-FAPI-04 administered 4.
Head-to-head Comparison of [Ga]Ga-FAPI-04 PET and [F]FDG PET in the Evaluation of Primary Gastrointestinal Tumors and Metastases: A Systematic Review and Meta-analysis.
Acad Radiol
June 2025
Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China (Y.Z., S.W., B.D., Y.C., Y.W., Y.W., J.Z., Y.L., X.L.). Electronic address:
Rationale And Objectives: Gastrointestinal cancers pose a major public health challenge due to very aggressive malignancy, the quick and widespread metastases, relapse frequently in lymph node and omentum, and poor prognosis. [Ga]Ga-FAPI-04 PET is widely used to diagnose gastrointestinal tumors. This study aimed to conduct a head-to-head comparison of the [Ga]Ga-FAPI-04 and [F]-FDG imaging methods for diagnosing primary gastrointestinal tumors and metastases.
View Article and Find Full Text PDFComparisons of [ Ga]Ga-FAPI-04 PET/CT with X-ray imaging in the assessment of patients with rheumatoid arthritis.
Clin Rheumatol
June 2025
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Objective: This study aimed to compare the value of [ Ga]Ga-FAPI-04 PET/CT with X-ray imaging in assessing disease activity and treatment response in patients with rheumatoid arthritis (RA).
Method: All patients underwent clinical and laboratory assessments, [ Ga]Ga-FAPI-04 PET/CT, and X-ray imaging, with a 6-month follow-up to assess disease activity and treatment response. Bland-Altman analysis assessed the agreement between PET/CT and X-ray parameters.
Distinguishing benign from malignant lesions with high [ Ga]Ga-FAPI-04 uptake in oncology patients: Insights from dynamic total-body [ Ga]Ga-FAPI-04 PET/CT.
Eur J Nucl Med Mol Imaging
March 2025
Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China.
Background And Purpose: While [ Ga]Ga-FAPI-04 PET/CT is widely used in various malignant tumors diagnosis, its specificity is challenged by high uptake in benign lesions such as inflammatory lymphadenopathy, bone fractures, and degenerative changes. This study aimed to quantitatively assess and characterize the metabolic heterogeneity of [ Ga]Ga-FAPI-04 uptake in benign and malignant lesions using dynamic total-body PET/CT.
Methods: Dynamic total-body [ Ga]Ga-FAPI-04 PET/CT scans (0-60 min post-injection) were performed on 17 oncology patients.
Targeting FAP-positive chondrocytes in osteoarthritis: a novel lipid nanoparticle siRNA approach to mitigate cartilage degeneration.
J Nanobiotechnology
October 2024
Department of Surgery of Spine and Spinal Cord, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 Weiwu Road, Zhengzhou, Henan Province, 450003, China.
Background: Osteoarthritis (OA) is a common joint disease that leads to chronic pain and functional limitations. Recent research has revealed soluble fibroblast activation protein (FAP) secreted from OA synovium could degrade type II collagen (Col2) in cartilage to promote the progression of OA. This study aimed to reveal the role of FAP from chondrocytes in OA and develop a novel lipid nanoparticle (LNP)-FAP siRNA delivery system for OA treatment.
View Article and Find Full Text PDF